Brief: Synact Pharma Receives EU Trial Approval For Study With Resomelagon
27/11/2024 06:34
Nov 27 (Reuters) - SynAct Pharma AB SYNACT.ST :
* SYNACT PHARMA RECEIVES EU TRIAL APPROVAL FOR THE PHASE 2B
ADVANCE STUDY WITH RESOMELAGON (AP1189)
Source text: ID:nMFNyVdgT
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development